Telix Pharmaceuticals (ASX:TLX) logged $0.1074 in EPS from continuing operations for the first half, compared with a loss of $0.0068 a year ago, a Thursday filing showed.
For the six months ended June 30, revenue from contracts with customers was $477.4 million versus $390.4 million previously, the Australia-listed pharmaceutical company added. Analysts surveyed by FactSet expected $479.6 million.
The company said it is on track to deliver in line with the upper end of its 2026 revenue guidance of $950 million to $970 million.